Urine Tenofovir Levels Strongly Correlate With Virologic Suppression in Patients With Human Immunodeficiency Virus on Tenofovir Alafenamide-based Antiretroviral Therapy

被引：3
|
作者：
Johnson, Kelly A. [1 ]
Okochi, Hideaki [1 ]
Arreguin, Mireya [1 ]
Watabe, Joseph [1 ]
Glidden, David, V [2 ]
Chattopadhyay, Anindita [1 ]
Imbert, Elizabeth [1 ]
Hickey, Matthew D. [1 ]
Gandhi, Monica [1 ]
Spinelli, Matthew [1 ]
机构：
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA
来源：
CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 05期
关键词：
tenofovir alafenamide; adherence; viral suppression; point-of-care monitoring; HIV; ADHERENCE;
D O I：
10.1093/cid/ciac828
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We found that urine tenofovir (TFV) levels >1500 ng/mL strongly predict virologic suppression among people with human immunodeficiency virus taking tenofovir alafenamide (odds ratio, 5.66; 95% confidence interval, 1.59-20.14; P = .007). This suggests an existing point-of-care assay developed for tenofovir disoproxil fumarate will support adherence monitoring for patients on all TFV-based antiretrovirals.
引用
收藏
页码：930 / 933
页数：4
相关论文
共 50 条
  • [1] Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus
    Ray, Adrian S.
    Fordyce, Marshall W.
    Hitchcock, Michael J. M.
    ANTIVIRAL RESEARCH, 2016, 125 : 63 - 70
  • [2] Renal safety of tenofovir alafenamide-based antiretroviral therapy in people with HIV: A mini-review
    Zhao, Fang
    Lu, Hongzhou
    BIOSCIENCE TRENDS, 2024, 18 (02) : 141 - 152
  • [3] Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy
    Alexandra Sjaarda
    Andrew Bernstein
    Andrew Sparks
    Saghar Saber
    Marc Siegel
    Infection, 2022, 50 : 407 - 412
  • [4] Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy
    Sjaarda, Alexandra
    Bernstein, Andrew
    Sparks, Andrew
    Saber, Saghar
    Siegel, Marc
    INFECTION, 2022, 50 (02) : 407 - 412
  • [5] Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
    Seo, Jun-Won
    Kim, Kichun
    Jun, Kang Il
    Kang, Chang Kyung
    Moon, Song Mi
    Song, Kyoung-Ho
    Bang, Ji-Hwan
    Kim, Eu Suk
    Kim, Hong Bin
    Park, Sang Won
    Kim, Nam Joong
    Choe, Pyoeng Gyun
    Park, Wan Beom
    Oh, Myoung-don
    INFECTION AND CHEMOTHERAPY, 2020, 52 (03): : 381 - 388
  • [6] Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide (TAF) in People With Human Immunodeficiency Virus (HIV)
    Damas, Jose
    Munting, Aline
    Fellay, Jacques
    Haerry, David
    Marzolini, Catia
    Tarr, Philip E.
    Steffen, Ana
    Braun, Dominique L.
    Stoeckle, Marcel
    Bernasconi, Enos
    Tshikung, Olivier Nawej
    Fux, Christoph A.
    Darling, Katharine E. A.
    Beguelin, Charles
    Wandeler, Gilles
    Cavassini, Matthias
    Surial, Bernard
    CLINICAL INFECTIOUS DISEASES, 2024, 79 (04) : 990 - 998
  • [7] Fanconi Syndrome in Patients With Human Immunodeficiency Virus Treated With Tenofovir-Based Antiretroviral Therapy: A Systematic Literature Review
    Joshi, Mrinmayee
    Clark, Brendan
    Lee, Todd A.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (08) : 857 - 869
  • [8] Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy
    Jullien, V
    Tréluyer, JM
    Rey, E
    Jaffray, P
    Krivine, A
    Moachon, L
    Lillo-Le Louet, A
    Lescoat, A
    Dupin, N
    Salmon, D
    Pons, G
    Urien, S
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) : 3361 - 3366
  • [9] Change in ratio levels of KIM-1 / urine creatinine and increase serum creatinine levels in human immunodeficiency virus (HIV) patients receiving tenofovir-based antiretroviral (ARV) combination therapy
    Murti, I. Dewa Gede Teguh Krisna
    Widiana, I. Gde Raka
    BALI MEDICAL JOURNAL, 2022, 11 (01) : 503 - 507
  • [10] No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide
    Johnson, Kelly A.
    Okochi, Hideaki
    Glidden, David, V
    Gandhi, Monica
    Spinelli, Matthew
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 88 (01) : 57 - 60
12345